Myriad Genetics (MYGN) said Wednesday the US Patent and Trademark Office issued two new patents to the company, further advancing the process of its molecular residual disease assay.
US patent No. 12,215,391 relates to proprietary automated methods to carry out molecular residual disease analysis, the company said late Wednesday. Patent No. 12,215,392 relates to the "patient journey" aspects of the disease.
The assay will be able to tell clinicians and patients if the treatment is and if the cancer has recurred, Myriad Chief Executive Paul Diaz said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.